http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2457351-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7c7159366be37ecf8a4c595cfa235a8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00
filingDate 2002-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2715080b8401c797d286bebcf9ae793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dae5e56a76ee8ea8860e2e7eaaa0d64e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c2765866b47ae6e1d4e511c2968947a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9f694e7e7ae4dfa15d87ca64d498c67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_692ede95c4a50b48df5309d26f4fe069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b084438d8b308e395474b386dc4191a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a6d39a8de6ad7119d93ae1fa59f898
publicationDate 2003-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2457351-A1
titleOfInvention Quinazolinone derivatives
abstract An optically active form of the quinazolinone derivatives represented by the general formula (1): (see formula 1) [wherein Y represents a phenyl group or C2-C7 alkyl group; E represents -CH= or nitrogen atom; and R represents a C1-C4 alkyl group and so on], or pharmaceutically acceptable salts thereof, has a selective antagonism for the M3 muscarinic receptor and depressant action on the frequency of rhythmic bladder contractions, and it is useful for the treatment of pollakiuria and urinary incontinence.
priorityDate 2001-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10293058
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID344381
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457313432
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556970
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421360260
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID947
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457444288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457308642
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10188852
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394834
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424558874
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450336627
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457280508
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457517809

Total number of triples: 42.